Nalbandian R M, Henry R L, Fleischman J A, Burek L, Williams G, O'Donnell F E, Diglio C A, Collier B D, Reeser F H
Med Hypotheses. 1982 Feb;8(2):155-62. doi: 10.1016/0306-9877(82)90098-6.
The erythrocytes of patients with sickle hemoglobin, diabetes, and Falciparum malaria adhere disproportionately to endothelial cells. Such pathophysiological activity compromises the microcirculation and results in clinical disease. Since Piracetam (2-oxo-1 pyrrolidine acetamide) has been shown to have a number of clinically beneficial actions on the formed elements of the blood including disengagement of adherent diabetic and sickle erythrocytes there is a rational basis for the trial of Piracetam as an adjuvant drug in SS disease and in diabetes mellitus to improve function of the microcirculation. For similar but somewhat more complex reasons Piracetam may potentiate the efficacy of anti-malarial drugs at any given dosage. Piracetam, a drug known to be safe in a decade of clinical usage, merits serious study in the 3 cited diseases.
患有镰状血红蛋白病、糖尿病和恶性疟的患者的红细胞与内皮细胞的黏附比例失调。这种病理生理活动会损害微循环并导致临床疾病。由于已证明吡拉西坦（2-氧代-1-吡咯烷乙酰胺）对血液中的有形成分具有许多临床有益作用，包括使黏附的糖尿病和镰状红细胞分离，因此有合理的依据试用吡拉西坦作为辅助药物用于镰状细胞病和糖尿病，以改善微循环功能。出于类似但更为复杂的原因，吡拉西坦可能会增强任何给定剂量抗疟药物的疗效。吡拉西坦是一种在十年临床应用中已知安全的药物，值得在上述三种疾病中进行认真研究。
